Inhibitory effect of thalidomide on the growth, secretory function and angiogenesis of estrogen-induced prolactinoma in Fischer 344 rats

Life Sciences

Volumn 79, Issue 18, 2006, Pages 1741-1748

  Stepień, Henryk ^a   Ławnicka, Hanna ^a   Mucha, Sławomir ^a   Wagrowska Danilewicz, Małgorzata ^b   Stepień, Bartłomiej ^a   Siejka, Agnieszka ^a   Komorowski, Jan ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b Department of Nephropathology ^*  (Poland)

Author keywords

Angiogenesis; Apoptosis; Cell proliferation; Pituitary tumors; PRL; Thalidomide; VEGF

Indexed keywords

ANGIOGENESIS INHIBITOR; CYCLINE; DIETHYLSTILBESTROL; ESTROGEN; IMMUNOMODULATING AGENT; PROLACTIN; THALIDOMIDE; VASCULOTROPIN;

ADENOHYPOPHYSIS; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL FUNCTION; CELL PROLIFERATION; CELL SECRETION; CONTROLLED STUDY; MALE; NICK END LABELING; NONHUMAN; PROLACTIN RELEASE; PROLACTIN SECRETING CELL; PROLACTINOMA; RAT; RAT STRAIN; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIGENS, CD31; APOPTOSIS; CELL NUCLEUS; CELL PROLIFERATION; DIETHYLSTILBESTROL; ESTROGENS; NEOVASCULARIZATION, PATHOLOGIC; PITUITARY GLAND; PITUITARY NEOPLASMS; PROLACTIN; PROLACTINOMA; PROLIFERATING CELL NUCLEAR ANTIGEN; RATS; RATS, INBRED F344; THALIDOMIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33748585464     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2006.06.013     Document Type: Article

References (59)

1. Banerjee S.K., Sarkar D.K., Weston A.P., De A., and Campbell D.R. Over expression of vascular endothelial growth factor and its receptor during the development of estrogen-induced rat pituitary tumors may mediate estrogen-initiated tumor angiogenesis. Carcinogenesis 18 (1997) 1155-1161
2. Banerjee S.K., Zoubine N.N., Tran T.M., Weston A.P., and Campbell D.R. Overexpression of vascular endothelial growth factor 164 and its co-receptor neuropilin-1 in estrogen induced rat pituitary tumors and GH3 rat pituitary tumor cells. International Journal of Oncology 16 (2000) 253-260
3. Bartlett J., Dredge K., and Dalgleish A. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nature Reviews. Cancer 4 (2004) 314-322
4. Brent R.E., and Holmes L.B. Clinical and basic science lessons from the thalidomide tragedy: what have we learned about the causes of limb defects?. Teratology 38 (1988) 241-251
5. Cracchiolo D., Swick J.W., McKiernan L., Sloan E., Raina S., Sloan C., and Wendell D.L. Estrogen-dependent growth of a rat pituitary tumor involves, but does not require, a high level of vascular endothelial growth factor. Experimental Biology and Medicine (Maywood, N.J.) 227 (2002) 492-499
6. Crane E., and List A. Immunomodulatory drugs. Cancer Investigation 23 (2005) 625-634
7. D'Amato R.J., Loughnan M.S., Flynn E., and Folkman J. Thalidomide is an inhibitor of angiogenesis. Proceedings of the National Academy of Sciences of the United States of America 91 (1994) 4082-4085
8. de la Torre N.G., Turner H.E., and Wass J.A. Angiogenesis in prolactinomas: regulation and relationship with tumour behaviour. Pituitary 8 (2005) 17-23
9. Eisen T., Boshoff C., Mak I., Sapunar F., Vaughan M.M., Pyle L., Johnston S.R., Ahern R., Smith I.E., and Gore M.E. Continuous low dose thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. British Journal of Cancer 82 (2000) 812-817
10. Elias K.A., and Weiner R.I. Direct arterial vascularization of estrogen-induced prolactin secreting anterior pituitary tumors. Proceedings of the National Academy of Sciences of the United States of America 81 (1984) 4549-4553
11. Ferrara N. Vascular endothelial growth factor and the regulation of angiogenesis. Recent Progress in Hormone Research 55 (2000) 15-35
12. Fine H.A., Wen P.Y., Maher E.A., Viscosi E., Batchelor T., Lakhani N., Figg W.D., Purow B.W., and Borkowf C.B. Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. Journal of Clinical Oncology 21 (2003) 2299-2304
13. Folkman J. A novel anti-vascular therapy for cancer. Cancer Biology & Therapy 3 (2004) 338-339
14. Gavrieli Y., Sherman Y., and Ben-Sasson S.A. Identification of programmed cell death via specific labeling of nuclear DNA fragmentation. Journal of Cell Biology 119 (1992) 493-501
15. Heaney A.P., Horwitz G.A., Wang Z., Singson R., and Melmed S. Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis. Nature Medicine 5 (1999) 1317-1321
16. Hus M., Dmoszynska A., Kocki J., Hus I., Jawniak D., Adamczyk-Cioch M., and Grzasko N. Long-term thalidomide therapy resulted in lack of mdr1 gene expression in a patient with primary resistant multiple myeloma. Leukemia 19 (2005) 1497-1499
17. Hyder S.M., Nawaz Z., Chiappetta C., and Stancel G.M. Identification of functional estrogen response elements in the gene coding for the potent angiogenic factor vascular endothelial growth factor. Cancer Research 60 (2000) 3183-3190
18. Jakubowski J. Blood supply, blood flow and autoregulation in the adenohypophysis, and altered patterns in oestrogen induced adenomatous hyperplasia. British Journal of Neurosurgery 9 (1995) 331-346
19. Jugenburg M., Kovacs K., Stefaneanu L., and Scheithauer B.W. Vasculature in nontumorous hypophyses, pituitary adenomas, and carcinomas: a quantitative morphologic study. Endocrine Pathology 6 (1995) 115-124
20. Kenyon B.M., Browne F., and D'Amato R.J. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Experimental Eye Research 64 (1997) 971-978
21. Kim K., Yoshida D., and Teramoto A. Expression of hypoxia-inducible factor 1alpha and vascular endothelial growth factor in pituitary adenomas. Endocrine Pathology 16 (2005) 115-121
22. Knight R. IMiDs: a novel class of immunomodulators. Seminars in Oncology 32 (2005) S24-S30
23. Komorowski J., Jankiewicz J., and Stêpieñ H. Vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) and soluble interleukin-2 receptor (sIL-2R) concentrations in peripheral blood as markers of pituitary tumors. Cytobios 101 (2000) 151-159
24. Kruse F.E., Joussen A.M., Rohrschneider K., Becker M.D., and Volcker H.E. Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor. Graefe's Archive for Clinical and Experimental Ophthalmology 236 (1998) 461-466
25. Kulke M.H., Stuart K., Enzinger P.C., Ryan D.P., Clark J.W., Muzikansky A., Vincitore M., Michelini A., and Fuchs C.S. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. Journal of Clinical Oncology 24 (2006) 401-406
26. Kumar S., Witzig T.E., Dispenzieri A., Lacy M.Q., Wellik L.E., Fonseca R., Lust J.A., Gertz M.A., Kyle R.A., Greipp P.R., and Rajkumar S.V. Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma. Leukemia 18 (2004) 624-627
27. LeBlanc R., Hideshima T., Catley L.P., Shringarpure R., Burger R., Mitsiades N., Mitsiades C., Cheema P., Chauhan D., Richardson P.G., Anderson K.C., and Munshi N.C. Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood 103 (2004) 1787-1790
28. Levy A., and Lightman S. Molecular defects in the pathogenesis of pituitary tumours. Frontiers in Neuroendocrinology 24 (2003) 94-127
29. Li X., Liu X., Wang J., Wang Z., Jiang W., Reed E., Zhang Y., Liu Y., and Li Q.Q. Thalidomide down-regulates the expression of VEGF and bFGF in cisplatin-resistant human lung carcinoma cells. Anticancer Research 23 (2003) 2481-2487
30. Lloyd R.V. Estrogen-induced hyperplasia and neoplasia in the rat anterior pituitary gland. An immunohistochemical study. American Journal of Pathology 113 (1983) 198-206
31. McCabe C.J., Boleaert K., Tannahill L.A., Heaney A.P., Stratford A.L., Khaira J.S., Hussain S., Sheppard M.C., Franklyn J.A., and Gittoes N.J.L. Vascular endothelial growth factor, its receptor KDR/Flk-1, and pituitary tumor transforming gene in pituitary tumors. Journal of Clinical Endocrinology and Metabolism 87 (2002) 4238-4244
32. Melmed S. Mechanisms for pituitary tumorigenesis: the plastic pituitary. The Journal of Clinical Investigation 112 (2003) 1603-1618
33. Meyer R.K., and Clifton K.H. Effect of diethylstilbestrol-induced tumorigenesis on the secretory activity of the rat anterior pituitary gland. Endocrinology 58 (1956) 686-693
34. Miller W.R., and Langdon S.P. Steroid hormones and cancer: (III) observations from human subjects. European Journal of Surgical Oncology 23 (1997) 163-177
35. Ochoa A.L., Mitchner N.A., Payntner C.D., Morris R.E., and Ben-Jonathan N. Vascular endothelial growth factor in the rat pituitary: differential distribution and regulation by estrogen. Journal of Endocrinology 165 (2000) 483-492
36. Oishi Y., Okuda M., Takahashi H., Fujii T., and Mori S. Cellular proliferation in the anterior pituitary gland of normal adult rats: influence of sex estrous cycle, and circadian change. The Anatomical Record 235 (1993) 111-120
37. Onofri C., Carbia Nagashima A., Schaaf L., Feirer M., Lohrer P., Stummer W., Berner S., Chervin A., Goldberg V., Stalla G., Renner U., and Arzt E. Estradiol stimulates vascular endothelial growth factor and interleukin-6 in human lactotroph and lactosomatotroph pituitary adenomas. Experimental and Clinical Endocrinology and Diabetes 112 (2004) 18-23
38. Pandey J., Bannout A., and Wendell D.L. The Edpm5 locus prevents the 'angiogenic switch' in an estrogen-induced rat pituitary tumor. Carcinogenesis 25 (2004) 1829-1838
39. Persson I. Estrogens in the causation of breast, endometrial and ovarian cancers-evidence and hypotheses from epidemiological findings. Journal of Steroid Biochemistry and Molecular Biology 74 (2000) 357-364
40. Phelps C., and Hymer W.C. Characterisation of oestrogen-induced adenohypophyseal tumors in the Fisher 344 rat. Neuroendocrinology 37 (1983) 23-31
41. Pisarek H., and Stepien H. The effect of mesulergine on prolactin secretion and anterior pituitary cells morphology in diethylstilboestrol-treated female Wistar rats. Histology and Histopathology 7 (1992) 111-117
42. Raje N., and Anderson K. Thalidomide and immunomodulatory drugs as cancer therapy. Current Opinion in Oncology 14 (2002) 635-640
43. Rosinol L., Cibeira M.T., Segarra M., Cid M.C., Filella X., Aymerich M., Rozman M., Arenillas L., Esteve J., Blade J., and Montserrat E. Response to thalidomide in multiple myeloma: impact of angiogenic factors. Cytokine 26 (2004) 145-148
44. Saeger W. Pituitary tumors: prognostic indicators. Endocrine 28 (2005) 57-66
45. Sampaio E.P., Sarno E.N., Gallily R., Cohn Z.A., and Kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. The Journal of Experimental Medicine 173 (1991) 699-703
46. Schechter J., Ahmad N., Elias K.A., and Weiner R. Estrogen-induced tumors: changes in vasculature in two strains of rat. American Journal of Anatomy 179 (1987) 315-323
47. Singhal S., Mehta J., Desikan R., Ayers D., Roberson P., Eddlemon P., Munshi N., Anaissie E., Wilson C., Dhodapkar M., Zeddis J., and Barlogie B. Antitumor activity of thalidomide in refractory multiple myeloma. The New England Journal of Medicine 341 (1999) 1565-1571
48. Son M.J., Kim J.S., Kim M.H., Song H.S., Kim J.T., Kim H., Shin T., Jeon H.J., Lee D.S., Park S.Y., Kim Y.J., Kim J.H., and Nam D.H. Combination treatment with temozolomide and thalidomide inhibits tumor growth and angiogenesis in an orthotopic glioma model. International Journal of Oncology 28 (2006) 53-59
49. Staples R.E., and Holtkamp D.E. Effects of parental thalidomide treatment on gestation and fetal development. Experimental and Molecular Pathology 26 (1963) 81-106
50. 3H]-thymidine incorporation by pituitary cells cultured in vitro. Endocrinology 109 (1981) 1784-1786
51. Stepien H., Grochal M., Zielinski K.W., Mucha S., Kunert-Radek J., Kulig A., Stawowy A., and Pisarek H. Inhibitory effects of fumagillin and its analogue TNP-470 on the function, morphology and angiogenesis of an oestrogen-induced prolactinoma in Fisher 344 rats. Journal of Endocrinology 150 (1996) 99-106
52. Stepien H.M., Kolomecki K., Pasieka Z., Komorowski J., Stepien T., and Kuzdak K. Angiogenesis of endocrine gland tumours-new molecular targets in diagnostics and therapy. European Journal of Endocrinology 146 (2002) 143-151
53. Takada K., Yamada S., and Teramoto A. Correlation between tumor vascularity and clinical findings in patients with pituitary adenomas. Endocrine Pathology 15 (2004) 131-139
54. Teo S.K., Stirling D.I., and Zeldis J.B. Thalidomide as a novel therapeutic agent: new uses for an old product. Drug Discovery Today 10 (2005) 107-114
55. Turner H.E., Nagy Z., Gatter K.C., Esiri M.M., Harris A.L., and Wass J.A. Angiogenesis in pituitary adenomas - relationship to endocrine function, treatment and outcome. Journal of Endocrinology 82 (2000) 1441-1445
56. Vermeulen P.B., Roland R., Mertens V., van Marck E., de Bruijn E.A., van Oosterom A.T., and Dirix L.Y. Correlation of intratumoral microvessel density and p53 protein overexpression in human colorectal adenocarcinoma. Microvascular Research 51 (1996) 164-174
57. Weidner N. Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Research and Treatment 36 (1995) 169-180
58. Wiklund J., Wertz N., and Gorski J. A comparison of estrogen effects on uterine and pituitary growth and prolactin synthesis in F344 and Holtzman rats. Endocrinology 109 (1981) 1700-1707
59. Yabu T., Tomimoto H., Taguchi Y., Yamaoka S., Igarashi Y., and Okazaki T. Thalidomide-induced antiangiogenic action is mediated by ceramide through depletion of VEGF receptors, and is antagonized by sphingosine-1-phosphate. Blood 106 (2005) 125-134